Story · Medicine & Biotech
David Aggen: Ongoing Phase III Trials Bring New Perspectives to First-Line mUC Treatment
1 outlet · first reported by OncoDaily on
David Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “Here are the phase III trials on-going for front-line mUC. Second time Tom Powles used win on (OncoDaily)
Coverage, in order
-
David Aggen: Ongoing Phase III Trials Bring New Perspectives to First-Line mUC TreatmentDavid Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “Here are the phase III trials on-going for front-line mUC. Second time Tom Powles used win on
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.